Study #2018-0020
Phase II Study of Venetoclax Added to Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed by Consolidation with Cladribine Plus LDAC Alternating with 5-Azacitidine with Venetoclax in Patients with Untreated AML
MD Anderson Study Status
Enrolling
Treatment Agent
Azacitidine, Cladribine, Cytarabine, Venetoclax
Description
This phase II trial studies how well venetoclax, cladribine, low dose cytarabine, and azacitidine work in treating patients with acute myeloid leukemia that has previously not been treated. Drugs used in chemotherapy, such as venetoclax, cladribine, and low dose cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax, cladribine, low dose cytarabine induction followed by cladribine, low dose cytarabine, and azacitidine consolidation may work better in treating patients with acute myeloid leukemia.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia
Study phase:
Phase II
Physician name:
Tapan Kadia
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.